BeyondBio Inc.

Quick facts

Phase 2 pipeline

• BEY2153 · Oncology
  BEY2153 is a small molecule that targets the PI3K pathway.

Phase 1 pipeline

• BEY1107

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• BeyondBio Inc. portfolio CI brief
• BeyondBio Inc. pipeline updates RSS